HOME >> MEDICINE >> NEWS
Enbrel provides sustained clinical improvements for ankylosing spondylitis for up to 3 years

THOUSAND OAKS, Calif., November 13, 2006 -- Amgen (NASDAQ: AMGN), today announced that data from an ongoing open-label, multinational, phase 4 extension study showed that patients with ankylosing spondylitis (AS) who received treatment with Enbrel? (etanercept) experienced sustained improvement in signs and symptoms, spinal mobility and physical function over 148 to 160 weeks of therapy. These results are consistent with an ENBREL phase 3 clinical trial at 24 weeks. The 160-week results will be presented at the American College of Rheumatology (ACR) Scientific Meeting in Washington, D.C.

"These data demonstrate that ENBREL can provide substantial long-term improvement in AS symptoms such as total back pain and spinal mobility," said Joachim Sieper, M.D., professor of rheumatology, Charite University in Berlin, Germany. "Because AS is a chronic inflammatory disease that requires ongoing management, it is important to offer patients a treatment option that is effective, has an established safety profile, and can be used over the long-term."

Data presented at ACR showed that 59 patients who received open-label ENBREL treatment for up to 160 weeks experienced sustained clinical improvements. Overall, 78 percent of patients (n=46) continuing treatment with ENBREL achieved a 20 percent improvement in the Assessment on Ankylosing Spondylitis Response Criteria (ASAS 20) after 160 weeks of treatment. ASAS is a composite measure of improvement in AS symptoms that include total back pain, patient assessment of disease activity, inflammation and physical function. Thirty-one percent of patients (n= 18) achieved partial remission at week 160. Partial remission, as defined by ASAS, is a low disease activity level (score < 20 units out of 100 in each of the four ASAS criteria).

Additional ENBREL data presented at ACR from this phase 4 extension study show that improvement in spinal mobility was also sustained through 148 to 160 weeks of
'"/>

Contact: Sonia Fiorenza
805-447-1604
Porter Novelli
13-Nov-2006


Page: 1 2 3

Related medicine news :

1. Rheumatoid arthritis patients can benefit from Enbrel in combination with methotrexate
2. Sports concussion research using fMRI provides insight for safe return-to-play decisions
3. Fluorescence diffuse optical tomography provides high contrast, 3-D look at breast cancer
4. Daytrana provides significant effectiveness in both boys and girls with ADHD
5. New book provides unprecedented look at role of religion over a lifetime
6. New edition of medical reference book provides the latest in hematology
7. Lung cancer screening regimen provides opportunity for cure
8. MERLIN TIMI-36 study provides new safety and efficacy data for unique anti-anginal therapy
9. IceSAR campaign provides glimpse of future Sentinel-1 images over ice
10. Darunavir with FUZEON provides HIV patients a better chance to reach undetectable viral load
11. Optical technique provides improved virtual biopsies of internal surfaces

Post Your Comments:
(Date:8/28/2015)... Nevada (PRWEB) , ... August 28, 2015 , ... An ... its decision to make the purchase of CPAP equipment more affordable by offering shipping ... includes all types of CPAP products and orders of any size. My Cpap Store ...
(Date:8/28/2015)... ... August 28, 2015 , ... An article ... pizza maker Paul LaRocco has gone through to open a pizzeria in Westchester. Mr. ... process tends to take several months, but the current process, having already gone on ...
(Date:8/28/2015)... Falls Church, VA (PRWEB) , ... ... ... and Cybersecurity Risk Management for Medical Devices:, Understanding the FDA’s Position and ... – Rockville, MD, http://www.fdanews.com/cybersecuritymd , This workshop, chaired by internationally ...
(Date:8/28/2015)... , ... August 28, 2015 , ... On May 30th, ... joined as sponsor of the “Music With A Mission” benefit concert in Mendon, IL. ... event was to raise money to support music education programs in the underfunded local ...
(Date:8/28/2015)... ... August 28, 2015 , ... “ Frequentz ” was ... the latest and coolest applications on the market for iOS, Android, and Windows. Joe ... with viewers how this software allows businesses to track product movement from beginning to ...
Breaking Medicine News(10 mins):Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Track Product Movement from Beginning to End with Frequentz 2
(Date:8/28/2015)... CHAPEL HILL, N.C. , Aug. 28, 2015 ... critical market research projects can slow down the ... costs. It is, therefore, absolutely critical for biopharmaceutical ... the market research approval process for quicker and ... recent research by Best Practices, LLC, nearly three-quarters ...
(Date:8/28/2015)... , August 28, 2015 ... Market by Tumor (Breast, Lung, Prostate) Type (Protein & ... (Diagnostic, Drug Discovery, Prognostic) & Geography - Global Forecast ... is expected to reach around 17,689.0 Million USD by ... period of 2015 to 2020. Browse ...
(Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/686gwf/investigation ) ... on China,s Bevacizumab Market ,2010-2019" report to their ... name of Avastin, bevacizumab injection is the first angiogenesis ... approved by CFDA to treat metastatic colorectal cancer. Currently, ... all come from Roche and its subsidiary Genectech. In ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 5Investigation Report on China's Bevacizumab Market 2015-2019 2
Cached News: